7th Eurasian Hematology Oncology Summit
How I Treat Frontline ALL in 2020: Does Ph-Like Disease Have a Higher MRD+ Rate? Is ChemoRx+/- Rituximab Beneficial for OS/EFS in Burkitt Disease? Do We Need AlloSCT?
By
7th Eurasian Hematology Oncology Summit
FEATURING
Hagop Kantarjian
By
7th Eurasian Hematology Oncology Summit
FEATURING
Hagop Kantarjian
Login to view comments.
Click here to Login
